StockData
Stoke Therapeutics, Inc. logo

Stoke Therapeutics, Inc. (STOK) stock

STOKNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/30182% above fair value
$26.81−0.12 (-0.45%)

Close on Nov 20, 2026Market cap $1.73BP/E –Yield –

Stoke Therapeutics gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

No gross profit figures for Stoke Therapeutics

Stoke Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Stoke Therapeutics figures

See a number that looks wrong?